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Purpose: Acute anterior uveitis (AAU) is the most common form of uveitis and is thought to be autoimmune in nature.
Recent studies have described genes that act as master controllers of autoimmunity. Protein tyrosine phosphatase type 22
(PTPN22) and Cytotoxic T lymphocyte antigen-4 (CTLA-4) are two of these genes, and single nucleotide polymorphisms
(SNPs) in the genes encoding these molecules have been associated with several autoimmune diseases. In this study we
have analyzed SNPs in PTPN22 and CTLA-4 in patients with AAU.
Methods: The functional protein tyrosine phosphatase type 22 (PTPN22) SNP (R620W rs2476601, 1858C/T), and two
CTLA-4 SNPs (rs5742909, −318C/T and rs231775, 49A/G) were analyzed in 140 patients with AAU and 92 healthy
controls by sequence-specific primer -polymerase chain reaction (SSP-PCR). Data was analyzed by χ2 analysis and
Fisher’s exact test.
Results: There was no significant association between PTPN22 620W, CTLA-4 −318C/T, or CTLA-4 49A/G and AAU.
Similarly, there was no association with the three SNPs when patients were classified by race or gender. Finally, there
was no association with the presence of ankylosing spondylitis in the patient cohort.
Conclusions: The data do not support an association between SNPs in PTPN22 and CTLA-4, genes regarded as genetic
master switches of autoimmunity. This raises the issue of the etiology of AAU and the possibility that it should be regarded
as an autoinflammatory rather than an autoimmune condition.
Uveitis or inflammation of the uvea is a significant cause
of visual loss. Clinically, uveitis can be categorized into
distinct phenotypes. Acute anterior uveitis (AAU), which
presents unilaterally with sudden onset, is self-limiting and
recurrent and represents the specific uveitis phenotype
associated with ankylosing spondylitis (AS) and other
seronegative spondyloarthropathies (SpA) [1]. A link
between AAU, AS, and SpA is the major histocompatability
complex (MHC) class I molecule, human leucocyte antigen
B-27 (HLA-B*27). Although the frequency of patients with
AAU who are positive for HLA-B*27 varies among different
published surveys, it is generally estimated that among
Caucasian patients with AAU, 50% are positive for HLA-
B*27 [2].
It is clear that even in HLA-B27-associated AAU, other
genetic factors are involved. Several functional
polymorphisms in genes that produce proteins relevant to the
immune response have been described to either confer an
altered susceptibility to autoimmune diseases or appear to
influence their severity and outcome. Identification of such
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polymorphisms is important as it may help to advise patients
on prognosis and influence the choice and dose of
immunosuppressive drugs, particularly biological agents [3,
4].
A functional single nucleotide polymorphism (SNP) of
the gene encoding protein tyrosine phosphatase type 22
(PTPN22; R620W rs2476601, 1858C/T) has recently been
described as a strong common genetic risk factor for human
autoimmune disease [5]. PTPN22 is located on chromosome
1p13.3 and encodes a lymphoid-specific phosphatase (Lyp)
that binds to c-src tyrosine kinase (Csk), an intracellular
tyrosine kinase. Csk phosphorylates leucocyte-specific
tyrosine kinase (Lck), leading to the inhibition of Lck kinase
activity. The PTPN22 R620W mutation leads to reduced
binding of Lyp to Csk, resulting in reduced Lck inactivation,
with the overall effect of a gain of function mutation. This is
associated with downregulation of early T cell receptor
signaling that results in an increase in autoreactive T cells and
autoantibody production, a process thought to be due to
defective deletion of autoreactive T cells during thymic
maturation or dysfunction of regulatory T cells [6]. PTPN22
R620W has been associated with rheumatoid arthritis, type 1
diabetes mellitus, systemic lupus erythematosus, and
autoimmune thyroiditis. In contrast, PTPN22 R620W has not
been associated with two other presumed autoimmune
disorders, multiple sclerosis and Crohn’s disease [7,8].
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Human Cytotoxic T lymphocyte antigen-4 (CTLA-4) is
located on chromosome 2p33, and two well studied
polymorphisms in this gene are −318 C to T, (rs5742909) and
−49 A to G (rs231775). In particular, the 49G polymorphism
has been linked to reduced expression of CTLA-4 on the T
cell surface, reduced soluble CTLA-4 production, and
subsequently impaired inhibitory function [9]. The biological
importance of such a change is supported by the findings that
the 49 A/G SNP has been associated with Graves’ disease,
type 1 diabetes mellitus, primary biliary cirrhosis, and, in
combination with a second CTLA-4 SNP 6230 G/A, an
increased rate of acute rejection in patients undergoing liver
transplantation [10-12]. In this study, PTPN22 R620W,
CTLA-4 −318C/T, and CTLA-4 49A/G were tested for
association with disease in a cohort of patients with AAU.
Associations with race, gender, and presence of AS were also
tested.
METHODS
Subjects: One hundred and forty subjects with AAU were
recruited through Oregon Health and Science University,
Portland, OR. The diagnostic validation of AAU was based
on an ophthalmology chart review by J.R.S. The clinical
criteria for the diagnosis of AAU include documented
evidence through an assessment by slit-lamp biomicroscopic
examination of anterior chamber inflammation that is sudden
in onset, unilateral, and resolves within 12 weeks. This form
of uveitis is typically episodic, and although it presents
unilaterally, it may flip-flop, involving the companion eye in
recurrence. Individuals were considered to be affected with
uveitis if (1) they met the AAU criteria after careful review of
ophthalmology chart notes or (2) they were referred to the
study by a uveitis specialist with first-hand knowledge of the
subjects’ uveitis presentation. Ninety-two race and gender
matched healthy individuals were used as controls. This
research was conducted under human subject protocols
approved by the OHSU, the St. Thomas' Hospital, London and
the Sandwell and West Birmingham National health Service
Trust, Birmingham, UK local ethics committees and adhered
to the Declaration of Helsinki agreement.
Single nucleotide polymorphism analysis: After informed
consent, blood samples were collected by venepuncture.
Genomic DNA was prepared using standard salt extraction
techniques and stored at –70 °C until use. The PTPN22
R620W, CTLA-4 −318C/T, and CTLA-4 +49A/G SNPs were
detected by sequence-specific primer-polymerase chain
reaction (SSP-PCR) using primer mixes (Table 1).
Statistics: Associations with disease were sought between
allele frequencies. χ2 analysis was performed using EpiStat
(EpiStat Group Inc, Atlanta GA). A case-control analysis was
employed using the Fisher’s exact test.
RESULTS
The AAU cohort consisted of 140 subjects (78 female, 62
male) with 133 identified Caucasian by self-report. Of the 140
with AAU, 76 were without history of AS while 58 had a
diagnosis and the remaining six subjects were considered to
have probable or early signs of AS. The healthy control cohort
represented 92 subjects (54 female, 38 male), 81 of whom
were Caucasian.
The minor allele frequencies of CTLA-4 −318 and +49
were 8.9% and 42.1%, respectively, in the AAU group, and
4.9% and 36.4%, respectively, in the healthy controls.
Although we noted slightly higher minor allele frequencies of
both SNPs in the AAU group, the differences were not
statistically significant (Table 2). The SNP allele frequencies
in the control group were in agreement with other published
Caucasian cohorts [9]. Furthermore, sub-analyses with only
the Caucasian samples or only the subjects without AS or a
haplotype analysis of the two SNPs (Table 2) did not reveal
any significant differences between the cases and controls.
The PTPN22 R620W variant allele frequency was 9.8%
in the healthy control cohort, which was similar to a UK
control cohort and other published reports [7,13]. This was
higher than the variant allele frequency found in the AAU
group (6.5%), but this difference was not statistically
significant (p=0.217; Table 3). By restricting the analysis to
Caucasian samples, the variant allele frequency was 11.1%
and 6.8% in controls and AAU patients, respectively
(p=0.151). Furthermore, sub-analysis of only those AAU
subjects without AS revealed no difference between controls
(9.8%) and cases (9.21%, p=1.000).
DISCUSSION
Acute anterior uveitis (AAU) is the most common form of
immune-mediated uveitis and is strongly associated with
HLA-B27 and spondyloarthritis. In this study, we sought to
determine if polymorphisms in genes encoding genetic master
TABLE 1. PCR PRIMER SEQUENCES AND LENGTH OF AMPLIFICATION PRODUCT.
Gene Allele Sequence 5′-3′ Control primer
CTLA4 −318C CACTTAGTTATCCAGATCCTC TGCCAAGTGGAGCACCCA A
−318T CACTTAGTTATCCAGATCCTT GCATCTTGCTCTGTGCAGAT
49A CAGGGCCAGGTCCTGGT
49G CAGGGCCAGGTCCTGGC Product 745 basepairs
Product 402 basepairs
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switches, PTPN22 and CTLA-4, contribute to AAU. The
results show that neither PTPN22 R620W nor CTLA-4 SNPs
(−318, +49) are associated with AAU in this cohort. As the
PTPN22 620W frequency varies in different geographical
areas, we analyzed only the Caucasians in our cohort and again
found no significant association. Finally, there was no
association between any of the polymorphisms tested and AS
in the patient group. These data show that PTPN22 and
CTLA-4 polymorphisms do not influence onset or severity of
AAU.
As stated, AAU has been strongly linked to HLA-B*27
and SpA. In recent studies, uveitis has been described as a first
symptom in nearly half of SpA patients [14]. AAU has also
been associated with early onset of SpA in HLA-B*27-
positive patients [15]. Conversely, patients with an
extraocular disease have a greater number of uveitis relapses
compared to ocular disease alone. These studies involved
patients at tertiary referral centers. By comparison, in a
primary care setting, HLA-B*27, AS, or family history of AS
did not influence relapses in these patients whereas patients
with one relapse were more likely to have a second event
[16]. Therefore, HLA-B*27 appears to be involved with more
severe AAU.
AAU has been classified as an autoimmune condition.
However, the evidence to support this is lacking. Numerous
studies have shown serum antibodies to Gram negative
bacteria, including Helicobacter pylori, Chlamydia
trachomatis, Salmonella, and Proteus sp, in HLA-B*27–
TABLE 2. ALLELE FREQUENCY AND GENOTYPE ANALYSIS OF CTLA-4 −318 AND +49 POLYMORPHISMS IN PATIENTS WITH AAU AND HEALTHY
CONTROLS.
AAU patients                                  Controls
     (n=140)                                         (n=92)                                           p valueCTLA-4 −318
C 0.91 0.95 0.14
T 0.09 0.05
Genotype
CC 123 83 ns
CT 15 9
TT 2 0
CTLA-4 +49
A 0.58 0.64 0.24
G 0.42 0.36
Genotype
AA 49 38 ns
AG 64 41
GG 27 13
CTLA-4 Haplotype
CA 138 108 0.06
CG 117 67 0.29
TA 25 9 0.15
TT 0 0 -
There was no significant differences in haplotype or genotype frequency between patients with AAU and healthy controls.
ns=not significant.
TABLE 3. ALLELE FREQUENCY AND GENOTYPE ANALYSIS OF PTPN22 620W POLYMORPHISM IN PATIENTS WITH AAU AND HEALTHY
CONTROLS.
PTPN22
AAU patients                                Controls 
   (n=140)                                         (n=92)                                          p value
Allele Frequency
C 0.93 0.90                                               0.2
T 0.07 0.10
Genotypes
CC 123 75 ns
CT 14 16
TT 2 1
There was no significant differences in haplotype or genotype frequency between patients with AAU and healthy controls.
ns=not significant.
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positive and SpA patients. In particular, the response to H.
pylori was greater in patients compared to healthy controls,
although this may have been biased by the lack of HLA-B*27
in the control group [17]. Neutrophils and monocytes from
patients with active AAU have a decreased expression of Toll-
like receptor 2 (TLR2), and reduced cytokine production on
signaling through TLR4, which suggests a defect in response
to a microbial trigger, and a defect in response to pathogens
may be involved in AAU [18].
The lack of association between the SNPs of PTPN22 and
CTLA-4 and AAU does not support dysfunction in the
adaptive immune response. Therefore, the possibility exists
that the defect is in the innate immune system and that AAU
is autoinflammatory rather than autoimmune.
Autoinflammation is described as local factors at sites
predisposed to disease, leading to the activation of innate
immune cells including macrophages and neutrophils [19].
Recent genetic studies endorse such a scenario.
Polymorphisms in tumor necrosis factor (TNF; -308A and
-238A), which are associated with increased production of the
cytokine, are significantly more frequent in HLA-B*27–
positive patients [20]. Similarly, HLA-B*27–positive patients
with extraocular disease show an association with SNPs in the
TNFRSF1A gene (TNFR1) compared to patients with AAU
alone [21]. Interestingly, anti-TNF therapy has been shown to
decrease the number of anterior chamber cells rapidly, to
speed resolution of disease, and to reduce the rate of relapse
on follow-up [22,23]. A SNP in the gene encoding CCL-2
(−2518G), which is associated with significantly higher
production of a chemokine involved in monocyte and
neutrophil migration, was significantly associated with HLA-
B*27–positive AAU [24]. Increased production and response
to TNF in response to infection and exacerbated by the
presence of HLA-B*27 [25] would lead to endothelial
activation and increased chemokine expression in many sites
including the eye with the resultant influx of blood leucocytes,
the majority of which would not be ocular specific. The self-
limiting and relapsing nature of AAU could be explained by
these mechanisms
However, other genes are involved in AAU. A recent
whole genome SNP analysis comparing patients with AAU
and patients with AS identified a region of chromosome 9 that
was linked to AAU but not AS unlike most of the other
hotspots [26]. The specific genes involved are currently being
investigated.
CTLA-4 polymorphisms have been reported in other
ocular diseases. Similar to the findings in the current study,
−318C/T and 49A/G were not significantly associated with
intermediate uveitis or Behcet’s disease [13]. Conversely, in
Chinese patients with Vogt-Koyanagi-Harada (VKH)
syndrome 49G, and a haplotype based on four CTLA-4 SNPs,
linked to reduced function, were associated with susceptibility
to the syndrome [27]. In patients with Fuch's heterochromic
cyclitis CTLA-4 -318T and a microsatellite repeat, linked to
increased function, were associated with disease [28]. These
differences may be explained by the nature of the disease type,
autoimmune (VKH) or infectious (FHC), compared to
idiopathic uveitis or possibly due to ethnic differences. These
aspects should be investigated in future studies.
There are caveats in our study. The SNPs tested are not
the only ones reported for these genes, and it remains possible
that other mutations may influence AAU. Similarly, other
genes including NOD2 and FOXP3 are regarded as master
switches of autoimmunity, and these genes were not included
in this study. In conclusion, the lack of association between
SNPs in the genetic master switches of autoimmunity,
PTPN22 and CTLA-4, suggests that regardless of the strong
linkage with HLA-B*27, AAU should be regarded as an
autoinflammatory rather than an autoimmune condition.
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